Incyte 2025-26: Revenue $5.14B (+21%), Hematology +83%, Pipeline Inflection
FY25 revenue $5.14B (+21%); op income $1.34B (vs $80M FY24, massive recovery); NI $1.29B; EPS $6.41 (vs $0.15 FY24). Q4 revenue $1.51B (+28%). Jakafi FY $3.09B (+11%); Q4 $828M (+7%); prescriptions Q4 +11% / FY +9%. Opzelura FY $678M (+33%); Q4 $207M (+28%). Hematology + Oncology FY $583M (+83%); Q4 $187M (+121%) driven by Niktimvo + Manjuli + Zionis. Core business ex-Jakafi expected >30% growth FY26 / approaching $3-$4B by 2030. Multiple regulatory filings + pipeline readouts FY26. FY26 guide: revenue $4.77-$4.94B (+10-13% if including new launches differently, or strategic guide reflecting product launch contribution); Jakafi $3.22-$3.27B; Opzelura $750-$790M; Hematology Oncology $800-$880M; total GAAP R&D + SG&A $3.495-$3.675B (+4%).
Key takeaways
- Hematology + Oncology +83% FY25 / +121% Q4 — explosive growth. Niktimvo + Manjuli + Zionis driving. Q4 $187M / FY $583M. FY26 guide $800-$880M = continued double-digit growth. The structural transformation — diversification from Jakafi-dependent to multi-product oncology platform.
- Op income inflected from $80M FY24 → $1.34B FY25. EPS swung from $0.15 → $6.41. The earnings transformation reflects: revenue growth + Hematology/Oncology launches + R&D rationalization + Opzelura compounding + cost discipline. Major structural shift.
- Opzelura FY $678M (+33%) / Q4 $207M (+28%). Atopic dermatitis + vitiligo cream growing rapidly. Pediatric AD launch off to strong start. Moderate AD regulatory submission pending. Multi-indication expansion ongoing.
- Jakafi FY $3.09B (+11%) / FY26 guide $3.22-$3.27B. The legacy compounder. Polycythemia vera (PV) expected to be largest + fastest-growing indication FY26. Jakafi XR submission pending. Multi-year peak unclear but +11% FY25 demonstrates durable franchise.
- Pipeline transformation: multiple late-stage assets + readouts FY26. Mgmt explicit FY25 transformed pipeline. FY26 plans include additional approvals + regulatory filings + pivotal data readouts + trial initiations. Povastatinib for HS in Europe submitted.
Business
Incyte Corporation is a US biopharma focused on hematology + oncology + dermatology. Three primary product franchises + late-stage pipeline:
- Jakafi (ruxolitinib) (~60% of revenue). JAK1/2 inhibitor for myelofibrosis + polycythemia vera + graft-vs-host disease. FY $3.09B (+11%); Q4 $828M (+7%). Prescriptions Q4 +11% / FY +9%. PV expected to be largest + fastest-growing indication FY26. Jakafi XR (extended release) regulatory submission filed.
- Opzelura (ruxolitinib cream) (~13%). Topical JAK inhibitor for atopic dermatitis + vitiligo. FY $678M (+33%); Q4 $207M (+28%). Pediatric AD launch off to strong start; moderate AD submission pending; multi-indication expansion.
- Hematology + Oncology (~11%). Niktimvo + Manjuli + Zionis. FY $583M (+83%); Q4 $187M (+121%). The structural growth driver.
- Royalties + Other (~16%). Includes Jakavi (Novartis) royalties + Olumiant (Lilly) royalties + various licensing.
Strategic moves FY25:
- Jakafi FY $3.09B (+11%); prescriptions +9% FY / +11% Q4
- Opzelura FY $678M (+33%); pediatric AD launch
- Hematology + Oncology FY $583M (+83%); Q4 $187M (+121%) launches scaling
- Pipeline transformation completed
- Multiple late-stage assets advancing
- Jakafi XR regulatory submission
- Opzelura moderate AD regulatory submission
- Povastatinib for HS in Europe submission
- Q4 revenue $1.51B (+28% YoY)
- $19M FY25 buyback (vs $-2B FY24, -99% — much smaller program)
- $0 dividend
- 2030 vision: core business ex-Jakafi $3-$4B
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 3.39 | 3.70 | 4.24 | 5.14 |
| Revenue YoY | n/a | +9% | +15% | +21% |
| Op income ($B) | 0.60 | 0.65 | 0.08 | 1.34 |
| Op margin | 17.7% | 17.6% | 1.9% | 26.1% |
| Net income ($B) | 0.34 | 0.60 | 0.03 | 1.29 |
| Diluted EPS ($) | 1.52 | 2.65 | 0.15 | 6.41 |
| FCF ($M) | 892 | 449 | 249 | 1,355 |
| Capex ($M) | -78 | -47 | -86 | -59 |
| Total debt ($M) | 41 | 38 | 44 | 69 |
| Buyback ($B) | 0 | 0 | -2.00 | -0.02 |
The earnings progression: revenue 4-yr CAGR ~15%; op margin volatile reflecting R&D investment cycles + product launch costs (FY24 trough). Op income $80M FY24 → $1.34B FY25 ($1.26B inflection). EPS $0.15 → $6.41 (+$6.26 swing).
FCF $1.36B FY25 (+443% from $249M FY24) — exceptional cash flow generation reflecting product launches scaling + R&D rationalization. Capex remains light.
Total debt $69M FY25 — minimal debt; clean balance sheet.
Capital allocation
- Capex $-59M FY25 (-31% YoY). Asset-light biotech model.
- Dividends $0 (no dividend).
- Buybacks $-19M FY25 (vs $-2B FY24, -99%). Major buyback completed FY24; FY25 minimal.
- Debt $69M (basically minimal).
- FCF $1.36B (+443% vs FY24).
The capital allocation framework reflects biotech model: heavy R&D + selective M&A + pipeline asset acquisition + opportunistic buybacks. FY24 saw aggressive $-2B buyback; FY25 was light.
FY26 outlook (per Q4 2025 call, 2026-02-10)
| FY26 framework | Detail |
|---|---|
| Total revenue | $4.77B to $4.94B (+10-13%) |
| Jakafi net revenue | $3.22B to $3.27B (+4-6%) |
| Opzelura net revenue | $750M to $790M (+11-17%) |
| Hematology Oncology revenue | $800M to $880M (+37-51%) |
| Total GAAP R&D + SG&A | $3.495B to $3.675B (+4%) |
| Core business ex-Jakafi (LT) | >30% growth FY26; approaching $3-$4B by 2030 |
| Pipeline | Additional approvals + filings + pivotal data + trial initiations |
The FY26 framework: continued Jakafi durability + Opzelura compounding + Hematology Oncology +37-51% growth. Core ex-Jakafi targeting >30% growth. The pipeline catalyst calendar is loaded.
Key risks
Regulatory uncertainties. Multiple regulatory filings pending (Jakafi XR, Opzelura moderate AD, povastatinib HS Europe, others). Approval timelines uncertain.
Competitive pressures in AD + oncology. Atopic dermatitis (Eli Lilly Lebrikizumab + Sanofi/Regeneron Dupixent) + oncology (Bristol-Myers Squibb + AbbVie + Pfizer + others) — competitive intensity affects pricing + share.
Formulary access + pricing. Payer coverage policies + Medicare drug price negotiation + commercial formulary positioning affect Opzelura + Jakafi + Hematology economics.
Jakafi LOE timing. Jakafi loss of exclusivity 2027-2028 — generic ruxolitinib competition. The structural cliff for the largest revenue contributor. Multi-year preparation required.
Opzelura competitive dynamics. Topical AD market — branded competitors + biosimilars + generics emerging. Long-term pricing pressure.
Hematology + Oncology launch durability. Q4 +121% reflects launch scale; multi-year durability depends on competitive response + clinical evidence + payer access.
Pipeline late-stage outcomes. Late-stage clinical trial readouts — binary outcomes affecting revenue trajectory + capital requirements.
Pediatric AD launch traction. Opzelura pediatric AD off to strong start — sustainability + utilization patterns + payer coverage matter.
International expansion. Multi-country regulatory + commercial dynamics for new launches affect economics.
M&A pipeline. Strategic M&A or in-licensing required to offset Jakafi LOE; capital deployment + timing uncertain.
Manufacturing + supply chain. Specialty drug manufacturing reliability affects revenue + customer satisfaction.
Currency / FX. International revenue exposure.
Bottom line
Incyte FY25 is the structural transformation year: revenue +21% to $5.14B, op income $1.34B (vs $80M FY24), EPS $6.41 (vs $0.15), FCF $1.36B (+443%). Hematology + Oncology +83% FY ($583M); Q4 +121% ($187M) — Niktimvo + Manjuli + Zionis launches scaling. Opzelura +33% FY ($678M); pediatric AD launch off to strong start. Jakafi +11% FY ($3.09B); PV expected to be largest + fastest-growing indication FY26.
FY26 guide: total revenue $4.77-$4.94B (+10-13%); Jakafi $3.22-$3.27B; Opzelura $750-$790M; Hematology Oncology $800-$880M (+37-51%); GAAP R&D + SG&A $3.495-$3.675B (+4%). Core business ex-Jakafi expected >30% growth FY26; approaching $3-$4B by 2030.
The risks are real — regulatory uncertainties (multiple filings pending), competitive pressures in AD + oncology, formulary access + pricing, Jakafi LOE 2027-2028 (generic risk for largest revenue contributor), Opzelura competitive dynamics, Hematology + Oncology launch durability, pipeline late-stage outcomes, pediatric AD traction, international expansion, M&A pipeline, manufacturing + supply chain, FX.
But the structural thesis (Jakafi durable franchise + Opzelura multi-indication expansion + Hematology + Oncology launches scaling + late-stage pipeline transformation + 2030 vision $3-$4B core ex-Jakafi + cash generation $1.36B FY25) is intact and FY25 print confirms.
Quality biopharma compounder mid-product-portfolio-transformation. The Hematology + Oncology launches +83% / +121% Q4 + Opzelura +33% + Jakafi durability + late-stage pipeline + 2030 core ex-Jakafi $3-$4B target creates a multi-year compounding setup. Investors get exposure to oncology launches scaling + dermatology platform + pipeline upside + Jakafi durability + cash generation. The 2027-2028 Jakafi LOE is the structural cliff to monitor; the new launches + pipeline must scale to offset. FY26 catalyst calendar provides multiple paths to outperformance.
Citations
- Incyte Corporation FY25 Form 10-K (filed February 2026, SEC EDGAR).
- INCY Q4 2025 earnings call, 2026-02-10 — FY revenue $5.14B (+21%); Q4 $1.51B (+28%); Jakafi FY $3.09B (+11%) / Q4 $828M (+7%); prescriptions Q4 +11% / FY +9%; Opzelura FY $678M (+33%) / Q4 $207M (+28%); Hematology + Oncology FY $583M (+83%) / Q4 $187M (+121%); core business ex-Jakafi >30% growth FY26 / $3-$4B by 2030; FY26 guide (revenue $4.77-$4.94B; Jakafi $3.22-$3.27B; Opzelura $750-$790M; Hematology Oncology $800-$880M; GAAP R&D + SG&A $3.495-$3.675B).
- INCY Q3 2025 / Q2 2025 / Q1 2025 earnings calls — supporting Jakafi + Opzelura + Hematology Oncology launch dynamics + pipeline progression (assumed in line with Q4 trajectory).
- Internal financial_statements view (consolidated annual + cash flow + capital structure).